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SUMMARY 
An efficient two-step synthesis of the potential cholinergic neuronal mapping tracer 
[~~C]methylaminobenzovesamicol (MABV) is described. A tert-butoxycarbonyl 
protecting group was used to activate the aniline nitrogen of aminobenzovesamicol 
toward [ "Clmethyl iodide methylation under basic conditions. Following labeling, the 
protecting group was removed by brief acid treatment and the final product was 
purified by normal phase HPLC. The decay corrected yields of MABV are in the range 
of 30-70 %, based on 11C02, with a specific activity of 0.5-1.5 Ci/ pmol and synthesis time 
of less than 45 minutes. This new route makes clinical scale doses of this interesting 
compound available for human positron emission tomography studies. 
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INTRODUCTION 
There is considerable interest in the drug vesamicol as a pharmacological tool for 
study of the vesicular acetylcholine uptake system (1-3). Radiolabeled analogs of 
vesamicol show potential for mapping cholinergic neuron densities in the central 
nervous system (4-6), and heart (7). A promising 11C-analog under study is 
methylaminobenzovesamicol, [IICIMABV, (-)-(2R,3X)-tr~ns-5-(N-[~~C]methylamino)-2- 
hydroxy-3-(4-phenylpiperidino)-tetralin (5, 7). 
The original synthesis of [IIC]MABV involved direct 11C-methyl iodide 
methylation of alkanesulfonate salts of aminobenzovesamicol (ABV) (5 ,  B), but the 
relatively weak nucleophilicity of the aniline nitrogen required forcing conditions (115- 
125", 15 min, DMF) to speed the reaction. Side reactions and loss of [llClmethyl iodide 
by volatilization occurred at these high temperatures which considerably reduced 
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overall yields. Therefore, another route to MABV was sought which would be suitable 
for production of clinical scale batches (50-200 mCi) of this promising tracer. This report 
details an original two step synthesis of [11C]MABV using the trrt-butoxycarbonyl (BOC) 
protecting group to activate the aniline nitrogen toward methylation under basic 
conditions, after which the “activating” group is removed by acid treatment. 
BOC-ABV [C-11)MABV 
RESULTS AND DISCUSSION 
N-[I1C]methylation of secondary amides with (11CImethyl iodide under basic 
conditions is a facile reaction that has been utilized for labeling of methyl spiperone (9) 
I’K11195 (lo), and R0151788 (11). Benzanilides are readily N-alkylated in the presence of 
NaOH and tetraalkylammonium phase transfer catalysts under conditions which favor 
the formation of the anilide anion (12). Thus i t  was reasoned that an amide derivative 
of ABV could be methylated under similar conditions. Initial methylation experiments 
with N-acetyl-ABV and tetrabutylammonium hydroxide (TBAOH) showed a very 
quick reaction of this analog with methyl iodide at room temperature, but deacetylation 
of the intermediate to MABV proved too slow for the carbon-11 time frame. Therefore 
the more easily cleaved BOC derivative was examined. HPLC monitoring of model 
reactions of BOC-ABV with a limiting quantity of methyl iodide showed methylation 
to be complete within 1-5 min at room temperature in several solvents including DMF, 
CH3CN, CH2C12, and THF. Other acyl derivatives including benzyloxycarbonyl and 
ethoxycarbonyl were found to similarly activate the aniline nitrogen of ABV toward 
methylation (data not shown). I t  is noteworthy that protecting group bulk seemed to 
have no adverse effect on methylation yields. 
The anion of BOC-ABV appeared to form quickly after addition of TBAOH, 
judging from the development of a yellow color to the solution that could be 
discharged by adding excess methyl iodide or acid. Efficient and rapid methylation of 
BOC-ABV occurred with 0.5-2 stoichiometric equivalents of this base relative to 
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precursor. BOC-ABV/ TBAOH mixtures in THF remained stable and reactive toward 
methyl iodide for at least 10 min at room temperature according to HPLC monitoring of 
"cold" reactions. Nevertheless, as a general precation in radiosynthesis, the base was 
added just before the start and the BOC-ABV/ TBAOH solution was kept cold until 
[llCImethyl iodide addition was completed. 
Following methylation, the BOC group was removed in 3N HCl. In model 
reactions, cleavage was essentially complete within 1 minute at room temperature, but 
during actual radiosynthesis some spattering of labeled intermediate on the vessel 
walls from the passage of ["Clmethyl iodide usually occurred. Therefore, to insure 
thorough acid contact for BOC cleavage the solution was heated and agitated by 
bubbling carrier gas through the solution during this stage. 
Table. (11CIMABV Production Data 
Time of synthesis 33-45 min 
Radiochemical yield from target 11C (corr.) 30-70 % 
Yield (e.o.s., 15min/20 PA) 70-230 mCi 
Radiochemical purity > 98 % 
Chemical purity > 90 % 
Specific activity (e.0.s.) 0.5-1.5 Ci/ pmol 
Production data for 12 radiosyntheses are summarized in the Table. The overall 
radiochemical yield range is broad because it reflects the efficiencies of all steps of the 
synthesis, from in-target formation of and trapping of 11CO2, to final product isolation. 
Rapid semi-preparative normal phase HPLC system completely separated [IICIMABV 
from the large excess of pharmacologically active ABV (3a); no traces of the latter 
compound were ever detectable in the final product solution by analytical HPLC. The 
principal impurities encountered were small amounts of BOC-ABV and BOC- 
["CIMABV. Under normal cleavage and purification conditions the combined amount 
of these compounds did not exceed 10% of the mass of MABV in the final product 
solution. BOC-ABV and BOC-MABV are estimated to be an order of magnitude less 
pharmacologically active than MABV based upon their toxicities in mice (Mulholland 
et al., unreported results). 
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The traditional role of protecting groups in radiosynthesis is to mask the 
reactivity of competing functional groups toward unintended labeling or side reactions. 
In this work a "protecting" group has been used instead to selectively enhance the 
reactivity of the desired position. An efficient clinical scale synthesis of the cholinergic 
tracer [IICIMABV has been developed by taking advantage of the fact that under mild 
basic conditions acyl derivatives of ABV methylate at the aniline position much faster 
than ABV itself. Competing methylation at the piperidine nitrogen was insignificant, 
and the activating effects on the aniline nitrogen appeared to be independent of acyl 
group bulk. The high yields and flexibility in the choice of reaction solvent seen with 
the present example indicate this general approach may be useful for labeling of other 
aniline-containing compounds of interest. 
EXPERIMENTAL 
' H  NMR spectra were obtained in CDCl3 on a Bruker 360-MHz NMR 
spectrometer and are reported in parts per million downfield from tetramethylsilane. 
13C NMR spectra were measured at 90.56 MHz. Mass spectra were obtained on a 
Finnigan 4021 GC/MS system in the electron impact (EI) ionization mode. Molecular 
masses are given in atomic mass units (amu), followed by percent intensity relative to 
the most abundant ion. Elemental analysis was carried out by Spang Microanalytical 
Laboratory, Eagle Harbor, MI. Melting points were determined on a MEL-TEMP and are 
uncorrected. Flash chromatography utilized Merck 230-400 mesh silica gel. Thin-layer 
chromatography (TLC) used Analtech 0.25 mm plates with fluorescent background. 
THF was distilled from sodium-benzophenone ketyl immediately before use in 
radiosynthesis. TBAOH (lM, in methanol) was obtained from Aldrich. Carbon-11 
isotope in the form of COz was produced by bombarding high purity nitrogen gas in an 
aluminum target with 17 MeV protons (20 PA). Direct measurement of trapped 
[11C]C02 in the synthesis apparatus was impractical, so for the purposes of calculating 
overall radiochemical yields, starting activity was estimated from previously 
determined standard curves of 11C production values vs. irradiation time with this 
target. l l C  production from the target is approximately equal to theoretical thick target 
values calculated from cross section data (13). ['lCIMethyl iodide was produced through 
LiAlFLl reduction of [1'C]CO2 and subsequent treatment with HI (14). 
Racemic ABV and N-acetyl-ABV were prepared by published procedures (3a). 
The enantiomers of ABV were resolved by flash chromatography of the diastereomeric 
N,O-bis-(-)-a-methoxy-a-trifluoromethylphenylacetyl (MTPA) derivatives (15), 
followed by cleavage of the M M A  groups (16). Specific rotations of (-)- and (+)-ABV 
were [a Iz3~ = -58.lo(c =1.6, EtOH) and [a123~ = +54.7O(c =1.5, EtOH) , respectively. 
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Authentic MABV was synthesized through LiAlH4 reduction of the N- 
benzyloxycarbonyl derivative of (-)-ABV ((-)-(2R,3R)-trans-5-amino-2-hydroxy-3-(4- 
phenylpiperidino) tetralin). 
N-Benzyloxycarbonyl-ABV (BenzyI-(-)-(2R,3R)-trans-2-hydroxy-3-(4-phenyl- 
piperidino)-5-tetraZinyl carbarnate). Benzyl chloroformate (94 mg, 0.55 mmol) and 
Na2C03 (180 mg, 1.7 mmol) were added sequentially to a two phase solution of (-)-ABV 
(137 mg, 0.425 mmol) in H20: THF E t 2 0  (30 mL: 20 mL: 20 mL). The reaction mixture 
was stirred overnight at room temperature and poured into ethyl acetate (30 mL). The 
organic layer was separated, and the aqueous layer was extracted with ethyl acetate (2 x 
30 mL). The combined organic extracts were washed with saturated NaCl solution, 
dried over anhydrous Na2S04 and concentrated under reduced pressure. The crude 
product was flash chromatographed on silica, eluting with 40: 60 ethyl acetate: hexane, 
to afford 171 mg (88%) of N-benzyloxycarbonyl-ABV as a white solid, m.p. 76-78°C. IH 
NMR 61.69-1.97(m, 4H), 2.39(t, lH, J=11.1 Hz) 2.52-2.62(m, 2H), 2.67-2.97(m, 6H), 
3.33(dd, lH, J=16.2, 5.6 Hz), 3.84(ddd, lH, J=16.2, 10.3, 5.6 Hz), 5.23(s, 2H), 6.39(br.s, lH, 
NH), 6.93(d, lH, J=7.7 Hz), 7.14-7.60(m, 12H); MS (EI, 70 eV) m/z (relative intensity): 
456(65.5), 394(19.0), 348(81.2), 174(100.0), 160(39.7), 91(67.3); High-resolution MS (EI, 70 
eV), calcd. for C29H32N203: 456.2413, Found: 456.2417; Anal. Calcd for C29H32N203: C 
76.29; H: 7.06; N: 6.14. Found: C: 76.31; H: 7.19; N: 6.21. 
MABV ((-)-(2R,3R)-trans-5-(N-methylarnino)-2-hydroxy-3-(4-phenylpiperidino)- 
tetralin). LiAlH4 (0.75 mL of 1.OM in E t20 ,  0.75 mmol) was added dropwise to a 
solution of N-benzyloxycarbonyl-ABV (171 mg, 0.375 mmol) in dry THF (15 mL). The 
reaction mixture was refluxed with stirring for 5 hours and poured into 2N NaOH 
solution (30 mL). The aqueous layer was extracted with ether (3 x 30 mL), dried over 
anhydrous Na2S04 and concentrated under reduced pressure. The crude product was 
flash chromatographed on silica, eluting with 30:70 ethyl acetate/ hexane to afford 107 
mg (85%) of MABV as a white solid. m.p. 1600C; IH NMR 61.72-1.96(m, 4H), 2.39- 
3.00(m, 12H), 3.25(dd, lH, J=1.60,5.5 Hz) 3.52(br.s, 1H, NH) 3.86(ddd, 1H, J=16.0,10.5, 5.5 
Hz) 4.30(br.s, lH, OH) 6.49(d, lH, J=7.7 Hz) 6.56(d, lH, J=7.7 Hz), 7.12(t, 1H, 7.7 7.19- 
7.35(m, 5H); 13C NMR(CDC13): 6 20.54, 30.85 33.92, 34.40, 38.28, 43.01, 45.04, 53.53, 65.24, 
66.78, 107.03, 118.27, 118.98, 126.25, 126.80, 127.14, 128.47, 134.35, 146.03, 147.02; MS (EI, 70 
eV) m / z  (relative intensity): 336(M+, 53.7), 318(3.0), 203(4.4), 176(100.0), 158(61.7), 
144(20.4); High-resolution MS (EI, 70eV) calcd. for C22H28N20: 336.2202, Found: 
336.2198; Anal. Calcd for C22H28N20: C: 78.53, H: 8.39, N: 8.33. Found: C: 78.47; H: 8.31, 
N: 8.25. 
BOC-ABV (tert-ButyI-(-)-(2R,3R)-trans-2-hydrory-3-(4-phenylpiperidino)-5- 
tetralinyl carbarnate). Di-t-butyl dicarbonate (73 mg, 0.334 mmol) was added to a 
solution of (-)-ABV (49 mg, 0.152 mmol) in EtOH (2 mL), CHC13 (1 and 
triethylamine (0.5 mL) at room temperature. The resulting solution was stirred for 18 
hours and concentrated under reduced pressure. The residue was purified by flash 
chromatography on silica, eluting with 30:70 ethyl acetate/hexane, to afford 58 mg (90%) 
of BOC-ABV as a white solid, m.p. 145OC; IH NMR: 6 1.55(s, 9H), 1.73-1.97(m, 4H), 
2.47(td, lH, J=11.3, 2.0 Hz), 2.54-2.64(m, 2H), 2.78-3.00(m, 6II), 3.30(dd, lH, J=16.0, 5.6 Hz), 
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3.85(ddd, lH, J=14.7, 10.2,5.6 Hz), 6.16(br.s, lH, NI I), 6.89(d, IH, J=7.5 Hz), 7.15(t, lH, J=7.5 
Hz), 7.19-7.36(m, 5H), 7.57(d, lH ,  J=7.5 Hz); MS (EI, 70 eV), m/z(relative intensity): 
422(M+, 15.4), 366(5.8), 205(18.8), 188(8.9), 174(100), 160(71.6), 144(24), 130(31.6); High 
resolution MS (EI,70 eVO, calcd. for C2hH34hT203: 422.2569. Found: 422.2575; Anal. calcd. 
for C26H51N203: C= 73.90, H= 8.11, N= 6.63. Found: C= 73.67, H= 7.99, N= 6.70. 
Crystalline BOC-ABV and stock solutions in T€IF (6.7 mg /mL) were indefinitely 
stable at -20' over Drierite, but there were indications of slow decomposition (m.p. 
depression, TLC changes) over a several week period when the solid was stored at room 
temperature. 
[11C]MABV ( ( - ) - (2R ,3R) - t rans -5 - (~ -~~'C]n ie th~ lan i inc , ) -2 -hydroxy -3 - (4 -pheny~-  
pipmidino)-tetralin ), [*1C]Methyl iodide (15), in a 30-50 mL/ rnin N2 carrier stream, 
was passed into a -3OOC solution of BOC-ABV ( 1  mg, 2.4 pmol) and TBAH (2 pL of a 1M 
methanolic solution, 2 pmol) in 150 pL of dry THF. After accumulation of radioactivity 
in the solution had peaked, the conical reaction vessel was sealed and warmed to 60' 
for 1 min by means of a hot air gun. The heat was removed briefly while 150 pL of 6N 
methanolic HCl was added and then the reaction was returned to 60' for an additional 
minute. Carrier gas was passed through the solution at this point to throughly agitate it. 
The reaction solution was next made basic with 1M NH3, and the crude product was 
separated from water soluble materials by solid phase extraction using a 300 mg C-18 
silica (PrepSep, Fisher Scientific) column. The crude [IICIMABV was then purified 
with a 5 micron normal phase HPLC column (1 x 15 cm A/CN, ES Industries) and a 
nonaqueous solvent system of 9:l hexane: isopropanol at flow rate of 4 mL/ min. The 
[**C]MABV product eluted as a sharp peak a t  7.5 min. Retention times of other 
compounds of concern in this preparative system were: ABV: 11 min, BOC-ABV: 8.3 
min, and BOC-MABV: 5.5 min. After evaporation of the product fraction, [IICJMABV 
was formulated in sterile saline containing 10% ethanol. Samples of the final solution 
were checked for carrier mass and radiochemical purity by analytical reverse-phase 
IIPLC with serial UV (220 nm, Hitachi L4000) and radioactivity (CsF, Beckman 170) flow 
detectors. The analytical system consisted of a Regis 4.6 x 250 mm 5 micron C-18 
column with a solvent mixture of 3: 1: I CH3CN: MeOH: 0.02M KHP04- (pH 6.7). 
Capacity factors (k') in this System were: k'ABV: 1.76, k'MABV: 3.20, k'BOC-ABV: 3.80, 
and k'BOC-MABV: 4.70 The mass quantification sensitivity limit of this system for 
MABV and ABV, determined from standard injections in saline/ 10 % EtOH, was 
approximately 10 ng/25 pL of sample volume. Sensitivitity for BOC-ABV was slightly 
greater. 
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